Formation and interactions of cold and ultracold molecules: new challenges for interdisciplinary physics

Progress on researches in the field of molecules at cold and ultracold temperatures is reported in this review. It covers extensively the experimental methods to produce, detect and characterize cold and ultracold molecules including association of ultracold atoms, deceleration by external fields and kinematic cooling. Confinement of molecules in different kinds of traps is also discussed. The basic theoretical issues related to the knowledge of the molecular structure, the atom-molecule and molecule-molecule mutual interactions, and to their possible manipulation and control with external fields, are reviewed. A short discussion on the broad area of applications completes the review.Comment: to appear in Reports on Progress in Physic

Wet deposition of hydrocarbons in the city of Tehran-Iran

Air pollution in the city of Tehran has been a major problem for the past three decades. The direct effects of hydrocarbon contaminants in the air are particularly important such as their carcinogenic, mutagenic, and teratogenic effects which can be transported to other environments via dry and wet deposition. In the present study, rainwater samples were collected and analyzed for 16 polycyclic aromatic hydrocarbons (PAHs), benzene, toluene, ethyl benzene, and xylene (BTEX) as well as fuel fingerprints in two ranges of gasoline (C5–C11) and diesel fuel (C12–C20) using a gas chromatograph equipped with a flame ionization detector (GC/FID). Mean concentrations of ∑16 PAHs varied between 372 and 527 µg/L and for BTEX was between 87 and 188 µg/L with maximum of 36 µg/L for toluene. Both gasoline range hydrocarbons (GRH) and diesel range hydrocarbons (DRH) were also present in the collected rainwater at concentrations of 190 and 950 µg/L, respectively. Hydrocarbon transports from air to soil were determined in this wet deposition. Average hydrocarbon transportation for ∑PAHs, BTEX, GRH, and DRH was 2,747, 627, 1,152, and 5,733 µg/m2, respectively

RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion

Introduction: Nearly 1% to 2% of NSCLCs harbor RET fusions. Characterization of this rare population is still incomplete. Methods: This retrospective multicenter study included patients with any-stage RET positive (RET+) NSCLC from 31 cancer centers. Molecular profiling included DNA/RNA sequencing or fluorescence in situ hybridization analyses. Clinicobiological features and treatment outcomes (per investigator) with surgery, chemotherapy (CT), immune checkpoint blockers (ICBs), CT-ICB, multityrosine kinase inhibitors, and RET inhibitors (RETis) were evaluated. Results: For 218 patients included between February 2012 and April 2022, median age was 63 years, 56% were females, 93% had adenocarcinoma, and 41% were smokers. The most frequent fusion partner was KIF5B (72%). Median tumor mutational burden was 2.5 (range: 1–4) mutations per megabase, and median programmed death-ligand 1 expression was 10% (range: 0%–55%). The most common metastatic sites were the lung (50%), bone (43%), and pleura (40%). Central nervous system metastases were found at diagnosis of advanced NSCLC in 21% of the patients and at last follow-up or death in 31%. Overall response rate and median progression-free survival were 55% and 8.7 months with platinum doublet, 26% and 3.6 months with single-agent CT, 46% and 9.6 months with CT-ICB, 23% and 3.1 months with ICB, 37% and 3 months with multityrosine kinase inhibitor, and 76% and 16.2 months with RETi, respectively. Median overall survival was longer in patients treated with RETi versus no RETi (50.6 mo [37.7–72.1] versus 16.3 mo [12.7–28.8], p < 0.0001). Conclusions: Patients with RET+ NSCLC have mainly thoracic and bone disease and low tumor mutational burden and programmed death-ligand 1 expression. RETi markedly improved survival, whereas ICB may be active in selected patients